Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5209-5213

  Bulik, Catharine C ^a   Wiskirchen, Dora E ^a   Shepard, Ashley ^a   Sutherland, Christina A ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PENETRATION; FEMALE; HUMAN; INTERSTITIAL FLUID; MALE; MICRODIALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; THIGH; WOUND INFECTION;

AGED; ANTI-BACTERIAL AGENTS; DIABETES COMPLICATIONS; EXTRACELLULAR FLUID; FEMALE; HUMANS; MALE; MICRODIALYSIS; MIDDLE AGED; MINOCYCLINE; WOUND INFECTION;

EID: 78649644717     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01051-10     Document Type: Article

References (22)

1. Breedt, J., J. Teras, J. Gardovskis, F. J. Maritz, T. Vaasna, D. P. Ross, M. Gioud-Paquet, N. Dartois, E. J. Ellis-Grosse, and E. Loh. 2005. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob. Agents Chemother. 49:4658-4666.
2. Crandon, J. L., M. A. Banevicius, and D. P. Nicolau. 2009. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob. Agents Chemother. 53:1165-1169.
3. Darling, I. M., B. B. Cirincione, and J. S. Owen. 2005. Non-compartmental pharmacokinetics of tigecycline in phase 3 studies of patients with complicated skin and skin structure and intra abdominal infections. Abstr. 45th Annu. Meet. Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-20.
4. Dowzicky, M. J., and C. H. Park. 2008. Update on antimicrobial susceptibility rates among Gram-negative organisms in the United States: results from the tigecycline evaluation and surveillance trial (TEST) 2005-2007. Clin. Ther. 30:2040-2050.
5. Florescu, I., M. Beuran, R. Dimov, A. Razbadauskas, M. Bochan, G. Fichev, G. Dukart, T. Babinchak, C. A. Cooper, E. J. Ellis-Grosse, N. Dartois, and H. Gandjini. 2008. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J. Antimicrob. Chemother. 62:i17-i28.
6. Li, C., C. A. Sutherland, C. H. Nightingale, and D. P. Nicolau. 2004. Quantitation of tigecycline, a novel glycylcycline, by liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 811:225-229.
7. Lipsky, B. A. 2004. Medical treatment of diabetic foot infections. Clin. Infect. Dis. 39:S104-S114.
8. Lipsky, B. A., A. R. Berendt, H. G. Deery, J. M. Embil, W. S. Joseph, A. W. Karchmer, J. L. LeFrock, D. P. Lew, J. T. Mader, C. Norden, and J. S. Tan. 2004. Diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 39:885-910.
9. Lipsky, B. A., A. R. Berendt, J. Embil, and F. De Lalla. 2004. Diagnosing and treating diabetic foot infections. Diabetes Metab. Res. Rev. 20:S56-S64.
10. Mallick, R., A. Kuznik, and D. Weber. 2006. Treatment of complicated skin and skin structure infections in the U.S.: expected cost differences between tigecycline and vancomycin/aztreonam. Abstr. 16th Eur. Congr. Clin. Microbiol. Infect. Dis. (ECCMID); 1-4 April 2006, Nice, France, abstr. P1494.
11. Meagher, A. K., J. A. Passarell, B. B. Cirincione, S. A. Van Wart, K. Liolios, T. Babinchak, E. J. Ellis-Grosse, and P. G. Ambrose. 2007. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob. Agents Chemother. 51:1939-1945.
12. Müller, M. 2002. Science, medicine, and the future: microdialysis. BMJ 324:588-591.
13. Müller, M., O. Haag, T. Burgdorff, A. Georgopoulos, W. Weninger, B. Jansen, G. Stanek, H. Pehamberger, E. Agneter, and H. G. Eichker. 1996. Characterizations of peripheral-compartment kinetics of antibiotics by in vivo microdialysis. Antimicrob. Agents Chemother. 40:2703-2709.
14. Muralidharan, G., M. Micalizzi, J. Speth, D. Raible, and S. Troy. 2005. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49:220-229.
15. Ramsey, S. D., K. Newton, D. Blough, D. K. McCulloch, N. Sandhu, G. E. Reiber, and E. H. Wagner. 1999. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 22:382-387.
16. Rodvold, K. A., M. H. Gotfried, M. Cwik, J. M. Korth-Bradley, G. Dukart, and E. J. Ellis-Grosse. 2006. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 58:1221-1229.
17. Schmidt, S., R. Banks, V. Kumar, K. H. Rand, and H. Derendorf. 2008. Clinical microdialysis in skin and soft tissues: an update. J. Clin. Pharmacol. 48:351-364.
18. Sotto, A., N. Bouziges, N. Jourdan, J.-L. Richard, and J.-P. Lavigne. 2007. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol. Biol. 55:398-406.
19. Sun, H. K., C. T. Ong, A. Umer, D. Harper, S. Troy, C. H. Nightingale, and D. P. Nicolau. 2005. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother. 49:1629-1632.
20. Tentolouris, N., G. Petrikkos, N. Vallianou, C. Zachos, G. L. Daikos, P. Tsapogas, G. Markou, and N. Katsilambros. 2006. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin. Microbiol. Infect. 12:186-189.
21. Vardakas, K. Z., M. Horianopoulou, and M. E. Falagas. 2008. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res. Clin. Pract. 80:344-351.
22. Wyeth Pharmaceuticals Inc. 2010. Tygacil (tigecycline) package insert. Wyeth Pharmaceuticals Inc., Philadelphia, PA.